Major adverse cardiac events tend to occur more frequently in patients with acute myocardial infarction (AMI) caused by coronary artery atherosclerosis than by coronary artery spasm, a recent study has found.
High-risk atrial fibrillation (AF) patients with an endocardial left atrial appendage occlusion (LAAO) device may undergo direct current cardioversion (DCCV) without the need for oral anticoagulation (OAC) if preprocedural trans-oesophageal echocardiography shows good device position, suggests a study.
Use of ticagrelor alone among patients who underwent percutaneous coronary intervention (PCI) after 1-month dual antiplatelet therapy (DAPT) has shown noninferiority, but is not superior, to conventional treatment in the prevention of ischaemic events, reports a study. Major bleeding is also comparable between ticagrelor monotherapy and conventional treatment.
Children with familial hypercholesterolemia (FH) who receive statin therapy in childhood could potentially delay the progression of carotid intima-media thickness and reduce their risk of cardiovascular (CV) disease (CVD) in adulthood, according to a long-term follow-up study.
The use of a genotype-guided strategy for selection of oral P2Y12 inhibitor therapy appears to benefit patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), such that noncarriers of CYP2C19 loss-of-function alleles have favourable bleeding outcomes with clopidogrel vs standard treatment with ticagrelor or prasugrel, according to data from the POPular Genetics* trial.
Nearly one in 200 patients in a nationally representative cohort succumbs to early mortality following atrial fibrillation (AF) ablation, with most deaths occurring during 30-day readmission, according to a recent study. Early mortality is associated with procedural complications, congestive heart failure (CHF) and low hospital AF ablation volume.
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.
While a diagnosis of cancer is often met with concern and devastation, the same is barely true for heart failure. However, the mortality rate for those suffering from heart failure is worse than some common cancers, such as prostate and breast cancers.